1UK Prospective Diabetes Study (UKPDS) Groups.Inensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J].Lancet,1998,352(9131):837.
2Ohkubo Y,Kishikawa H,Araki L,et al.Intensive issulin therapy prevents the progression of diabetic microvascular complications in Japanese with non-insulin-dependent diabetes mellitus:a randomized prospective 6-yesr study[J].Diabetes Res Clin Pract 1995,28(2):103.
3Turner RC,Millns H,Neil HAW,et al.Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study (UPKDS:23)[J].BMJ 1998,316(7134):823.
4Usitupa MI,Niskanen LK,Siitonen O,et al.Ten-year cardiovascular mortality in relation to risk factors and abnormalityes in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects[J].Diabetologia,1993,36(11):1175.
5Rohlfing CL,Wiedmeyer,Little RR,et al.Defining the relationship between plasma glucose and HbA1c:ananlysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial[J].Diabetes Care,2002,25(2):275.
6Wright A,Burden ACF,Paisey RB,et al.Sulfonylurea inadequacy:efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK.Prospective Diabetes Study(UKPDS57)[J].Diabetes Care,2002,25(2):330.
7Turner RC,Cull CA,Frighi V,Holman RR.Glycemic control with diet,sulphonylurea,metformin,or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49)[J].JAMA,1999,281(21):2005.
8United Kingdom Prospective Diabetes Study Group.United Kingdom Prospective Diabetes Study (UKPDS013:relative efficacy randomly allocated diet,sulphonylurea,insulin,or metformin in patients with nemly diagnosed non-insulin dependent diabetes followed for three years)[J].BMJ,1995,310(6972):83.
9United Kingdom Prospective Diabetes Study Group.U.K.Prospective diabetes study 16.Overiew of 6 years' therapy of type Ⅱdiabetes:A progressive disease Diabetes[J].Diabetes,1995,44(11):1249.
10Stratton IM,Adler AI,Neil HA,et al.Association of glycaemia with macrovascular and microvascular coplication of type 2 diabetes(UKPDS 35):Lprospective observational study[J].BMJ,2000,321(7258):405.
二级参考文献12
1[1]Kraegen EW, James DE, Bennett SP, et al. In vivo insulin sensitivity in the rat determined by euglycemic clamp[J]. Am J Physiol, 1983,245 (Endocrinol, Metab, 8):E1-E7.
2[2]Storlien LH, Oakes ND, Pan DA, et al. Syndrome of insulin resistance in the rats: inducement by diet and amelioration with Benfluorex[J]. Diabetes, 1993,42:457-462.
3[3]Defronzo RA, Tobin JD, Andres. Glucose clamp technique: a method for quantifying insulin secretion and resistance[J]. Am J Physiol,1979,237 (Endocri-nol,Metab,Gastrointest,Physiol,6):E214-E223.
4[4]Coulston AM. The role of dietary fats in plant-based diets[J]. Am J Clin Nutr,1999,70(3 Suppl):512S-515S.
5[5]Rattigan S, Filsell OH, Reppucci D, et al. Impaired basal and epinephrine-stimulated glucose uptake by hearts from rats fed high-fat diets[J]. Nutr Rep Int,1983,28:603-612.
6[6]Hissin PJ, Karniele E, Simpson IA, et al. A possible mechanism of insulin resistance in the rat adipose cell with high-fat/low-carbohydrate feeding. Depletion of intracellular glucose transport systems[J]. Diabetes, 1982,31:589-592.
7[7]Storlien LH, James DE, Burleigh KM, et al. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats[J].Am J Physiol,1986,25(Endodrinol,Metab,14):E576-E583.
8[8]Ye JM, Doyle PJ, Iglesias MA, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation[J].Diabetes,2001,50(2):411-417.
9[9]Mannucci E, Bardini G, Ognibene A,et al. Comparison between 2 insulin sensitivity indexes in obese patients[J]. Diabetes Care, 2000, 23 (7):1042-1043.
10[10]Bokemark L, Froden A, Attvall S,et al. The euglycemic hyperinsulinemic clamp examination: variability and reproducibility[J]. Scand J Clin Lab Invest,2000 ,60(1):27-36.
